title: Characterization of a CD34+ cell line established from a child with large cell cutaneous lymphoma.
abstract: BACKGROUND
  Lymphoma presenting with skin involvement has heterogeneous morphology and rarely is seen in children. To study the pathogenesis of this disease, lymphoma cells from a child with B-cell large cell lymphoma of the skin were cultured in vitro.
  
  
  METHODS
  Lymphoma cells cultured on a feeder layer under hypoxic conditions grew in vitro after a latency period of 2 weeks. Since interleukin-6 (IL-6) induces final differentiation of activated B-lymphocytes, the cell line was evaluated for the presence of IL-6 receptors and biologic response to IL-6.
  
  
  RESULTS
  An Epstein-Barr virus (EBV)-negative cell line (UoC-B2) was established which expressed CD34, CD45, HLA-DR, CD19, CD20, sIgM, sIgD, and lambda light chain. Good general concordance was observed between the patient's lymphoma and the cell line by comparing the immunophenotype, genotype, and karyotype. The UoC-B2 cells expressed surface IgM but did not secrete IgM into the culture media even in the presence of supplemental IL-6.
  
  
  CONCLUSIONS
  A B-lymphoid cell line (UoC-B2) was established from a child with primary cutaneous lymphoma. The cells expressed cell surface IgM and receptors for IL-6 but supplemental IL-6 had no effect on IgM production or cell proliferation.
authors.affiliation: Department of Pediatrics, University of Chicago.
authors.forename: A N
authors.initials: AN
authors.lastname: Lorenzana
authors.forename: N R
authors.initials: NR
authors.lastname: McCabe
authors.forename: W R
authors.initials: WR
authors.lastname: Goodell
authors.forename: L Q
authors.initials: LQ
authors.lastname: Zhang
authors.forename: D
authors.initials: D
authors.lastname: Miley
authors.forename: M M
authors.initials: MM
authors.lastname: Le Beau
authors.forename: S
authors.initials: S
authors.lastname: Goldman
authors.forename: S D
authors.initials: SD
authors.lastname: Smith
mesh_terms: D015703:Antigens, CD; D018952:Antigens, CD34; D000951:Antigens, Neoplasm; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D007075:Immunoglobulin M / Q000096:biosynthesis; D016130:Immunophenotyping; D007223:Infant; D015850:Interleukin-6 / Q000494:pharmacology; D016393:Lymphoma, B-Cell / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D008297:Male; D011971:Receptors, Immunologic / Q000032:analysis; D019947:Receptors, Interleukin-6; D012878:Skin Neoplasms / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D014407:Tumor Cells, Cultured / Q000276:immunology*
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D000951:Antigens, Neoplasm; D007075:Immunoglobulin M; D015850:Interleukin-6; D011971:Receptors, Immunologic; D019947:Receptors, Interleukin-6